Seeking Alpha

Elan is holding an investors' meeting today, where shareholders are due to vote on four...

Elan is holding an investors' meeting today, where shareholders are due to vote on four proposals, including a share $200M buyback, a drug spin-off and a series of acquisitions. A vote in favor of any of the resolutions would void an offer of up to $8B from U.S. investment firm Royalty Pharma. Elan put itself up for sale on Friday, but still refused to engage with Royalty over the weekend, much to the latter's frustration. One imagines that Johnson & Johnson (JNJ) must be pleased to be well out of it, having last week sold the rest of its ADRs in Elan for $332.5M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|